spacer
home > epc
PUBLICATIONS

European Pharmaceutical Contractor

 

Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry – giving its pharma, biotech and CRO readership expert insight and analysis on the sponsor-service provider landscape.

EPC focuses on key trends, concerns and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis on building and managing effective collaborations.

Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands. With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas now have unrivalled access to a wealth of shared views and analyses.

For further information please contact:

Advertising
Nicholas Matthews 

Editorial
Tom Allaway

We're also on Twitter! Follow us @EPCmagazine

The latest digital edition of EPC can be viewed here
 

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.


epc
 
 
Featured in this issue

Trial Design Precautions

Suggestions for Success


Nuala Ronan and Deborah Arthur at Databean take a look at how regulations and increased costs can be reduced for small businesses and start-ups developing medical devices.

Clinical Trials
Enrolment Challenges

Global Goals

With elements ranging from clinical constraints to cultural and global regulations, coordinating a clinical trial can be challenging. Debbie Elliott, Colleen Grawe, Jaqueline Moore and Gina Steidle at Medpace examine the decisions involved.
  Clinical Trials
Designing First-in-Human Studies

Plotting the Route

Reaching that first-in-human trial is a significant step in all clinical research. Dr Torkel Gren at Recipharm Pharmaceutical Development and Anders Millerhovf at CTC Clinical Trial Consultants explore options for simplifying the process.

spacer



Published quarterly in
February, May,
August and November


Banner of EPC_Scope on Samedan
 
Banner of OCT_West_Coast_EPC on Samedan

Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

 
News and Press Releases

Navigating the new Clinical Trial Regulation with DIA

For those stakeholders involved with clinical trials in Europe, the new Clinical Trial Regulation to be introduced in 2019 will have a dramatic impact. The aim of the change in regulation is to increase the efficiency of all trials in Europe, as well as promoting research while avoiding the duplication of clinical trials
More info >>

air transport logo

 

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement